Key Takeaways
- Diversification pivot is now visible in the numbers: Agro dependence fell from 76% to 55% of revenue over four years, while Pharma grew 15x and high-performance materials tripled, reshaping the revenue base.
- Two acquisitions define the next chapter: Jayhawk (US manufacturing footprint) and Bliss GVS Pharma (CDMO/CMO platform) were both signed; full synergy benefits and consolidated financials will only show in FY27.
- Stand-alone growth ambition is aggressive: Management guided for a 20-30% CAGR over the next 3-5 years from the existing asset base, with peak revenue potential of ~INR3,500 cr from the current gross block and no major capex needed.
- Cash conversion improved sharply: Operating cash flow reached INR334 cr, exceeding PAT of INR222 cr, driven by better working capital management and asset utilization; further improvement is expected in FY27.
- What to watch next quarter: The consummation and integration plan for Bliss GVS, the pace of capacity utilization ramp at Bliss from 30% toward 60-70%, and whether the stand-alone growth trajectory sustains the promised 20-30% pace.
Diversification & Revenue Mix Shift
- Agro dependence structurally declining: Revenue contribution from agrochemicals fell from 76% in FY22 to 55% in FY26, a deliberate shift toward less cyclical, higher-value end-markets.
- Pharma scaling rapidly: Pharma revenue grew 15x from INR21 cr (FY22) to INR339 cr (FY26), driven by new customer additions and product approvals in regulated markets.
- High-performance materials tripled: Revenue from polymers and advanced materials rose from INR97 cr (FY22) to INR305 cr (FY26), reflecting successful commercialization of new chemistries.
- Pharma and polymer margin bias: These segments carry an upward bias to margins versus agro, but management will not guide until products are fully ramped; once at scale, the margin profile should be materially different.
- Order book supports continued mix shift: The order book and pipeline in Pharma and Polymer should deliver higher growth than agro going forward, while agro continues to recoup lost business.
Anand Desai: "Our dependence on agrochemicals has reduced from 76% revenue contribution in FY '22 to 55% in FY '26."
Bliss GVS Pharma Acquisition
- The deal: A definitive agreement to acquire 43.3% to 48.2% equity, plus an open offer for up to 26% additional shares from public shareholders; consummation expected in 2-3 months pending SEBI approval.
- Strategic logic: Bliss operates at only 30% capacity utilization, which can be quickly enhanced to 60-70%; it has limited presence in the US and Europe where Anupam is strong, and it opens the India pharma market.
- CDMO catalyst: A large CDMO project with a multinational pharma player (existing Bliss customer) is underway, supported by a separate INR250 cr capex at Halol; Anupam's involvement improves the probability, quality and value creation of that project.
- Funding structure: ~INR300 cr via non-convertible debentures, with the balance through non-controlling, non-voting equity instruments in a wholly owned subsidiary; management calls debt levels very comfortable against ~INR650+ cr EBITDA.
- EPS and value creation commitment: The acquisition will be EPS accretive from day one, and management aims to deliver value creation faster than the four years it took with Tanfac.
- Management continuity: The selling promoter (a senior citizen with succession considerations) will remain a non-participating, non-controlling shareholder; professional management stays in place, and Anupam will support and expand the team as needed.
- Integration philosophy: Integration does not require merging corporate entities; plants remain separate and are leveraged based on capacity, capabilities and strength of each organization, mirroring the Tanfac approach.
- Synergy timeline: Expansion in CDMO projects and regulated markets should start showing results in 6-12 months, with larger results in 18 months.
Gopal Agrawal: "Our vision is to create a dedicated pharmaceutical platform through Bliss GVS, which will serve as a primary vehicle for our future pharma CDMO and CMO opportunities."
Jayhawk & Manufacturing Footprint
- Jayhawk consolidation: Only one month and two days of Jayhawk performance are reflected in FY26 consolidated numbers; full synergy benefits will be visible in FY27.
- Strategic value: Jayhawk provides a US manufacturing footprint, strengthens advanced custom synthesis capabilities, and expands access to innovation-led and regulated markets including defense and semiconductors.
- Tanfac expansion: Tanfac is introducing new products and new customers in the current financial year, adding to the group's specialty chemical capabilities.
Stand-Alone Growth & Asset Utilization
- Growth trajectory recouped: FY26 delivered over 60-70% growth in stand-alone annual revenues, partly recouping two years of lost business; the base is now reset for sustained expansion.
- CAGR guidance: Management is reasonably confident in a 20-30% CAGR over the next 3-5 years on a stand-alone basis, driven by existing capacity and commercialized molecules.
- Peak revenue from current assets: The current gross block can support ~INR3,500 cr in peak revenue; no major capex is envisaged in the near future as existing capacity is sufficient for near-term growth.
- Capex cycle complete: INR315 cr was spent on the last leg of the capex program; all plants are now commercialized, shifting focus to sweating assets and converting working capital to cash.
- EV and Elementium contract: A specific contract in the EV space should drive significant growth, though details were not quantified.
Vishal Thakkar: "A growth of 20% to 25% or 30% growth rate over the next 3 to 5 years on a CAGR basis is something that we should be striving for and we should be looking at, and we feel reasonably confident on that performance."
Cash Flow & Balance Sheet
- Operating cash flow inflection: Consolidated OCF reached INR334 cr against PAT of INR222 cr, reflecting improved asset utilization, operational efficiency and better working capital management.
- Working capital trajectory: Inventory levels improved over the year in line with guidance; further improvement is expected in FY27, though Jayhawk's balance sheet items are not yet fully reflected.
- Debt comfort: With ~INR650+ cr in EBITDA (on an allocation basis), debt levels are very comfortable; most debt is working capital debt rather than term debt.
- Tax rate normalization: The stand-alone tax rate going forward should be around 25%.
Platform Strategy & Competitive Positioning
- Value chain coverage as moat: Management's thesis is that covering a larger portion of the value chain improves customer engagement, traction and probability of winning larger mandates.
- Regulated market leverage: Bliss has existing permissions and approvals in the US and Europe; Anupam can leverage its own expertise in regulated markets to expand Bliss's reach quickly.
- No conflict of interest concern: Management argues the pharma market is large enough that even at 5x current size (~$0.5 bn revenue), conflicts would not arise; they will be selective about therapies and product profiles. [15-16]
- Africa exposure: Anupam has no exposure to Africa; Bliss does, which is one part of the synergy and diversification logic.
Vishal Thakkar: "The larger the value chain that I can cover and offer to my customer, better -- and a better probability and better traction that I can see with my customer, better is the kind of engagement that I can have."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Stand-alone revenue CAGR | 20-30% CAGR | Next 3-5 years |
| Peak revenue from current gross block | ~INR3,500 cr | No specific date; current capacity sufficient |
| Bliss capacity utilization | Ramp from 30% to 60-70% | Near-to-medium term |
| Bliss synergy results | Initial results from CDMO, US, Europe, India expansion | 6-12 months; larger results in 18 months |
| Bliss EPS accretion | EPS accretive from day one | From consummation |
| Bliss value creation | Faster than Tanfac (which took 4 years) | No specific date |
| Working capital | Further improvement | FY27 |
| Stand-alone tax rate | ~25% | Going forward |
| Capex | No major capex envisaged | Near future |
| Bliss transaction consummation | SEBI approval and open offer results | 2-3 months estimated |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated total income | ₹639 cr, up 26% YoY from ₹506 cr |
| Consolidated revenue from operations (FY26) | ₹2,384 cr, up 65% YoY from ₹1,448 cr |
| Consolidated EBITDA (FY26) | ₹543 cr, margin of 23% vs ₹412 cr in FY25 |
| Consolidated EBITDA (Q4) | ₹141 cr, margin of 22% vs ₹150 cr in Q4 FY25 |
| Consolidated PAT (FY26) | ₹222 cr, margin of 9% vs ₹160 cr in FY25 |
| Consolidated PAT (Q4) | ₹56 cr, margin of 9% vs ₹63 cr in Q4 FY25 |
| Operating cash flow (FY26) | ₹334 cr consolidated, ₹274 cr standalone |
| Capex (FY26) | ₹315 cr, last leg of capex program; no major capex expected near-term |
| Standalone revenue mix (FY26) | Agrochemicals 55%, Pharma 20%, Performance Materials 18%, Personal Care 7% |
| Pharma revenue (FY26 standalone) | ₹339 cr, 15-fold growth from ₹21 cr in FY22 |
| Performance materials revenue (FY26 standalone) | ₹305 cr, threefold growth from ₹97 cr in FY22 |
| Order book | ~₹14,000 cr, with ~₹1,700–1,800 cr incremental annual revenue potential from pipeline |
| Gross debt (consolidated) | ~₹1,500 cr gross, ~₹1,100 cr net; over two-thirds working capital |
| Pro forma working capital days | 215–220 days consolidated including Jayhawk; 240–250 days excluding Jayhawk |
| Standalone peak revenue potential from current gross block | ~₹3,500 cr |
| Maintenance capex guidance | ₹50–75 cr per year |
| Standalone tax rate guidance | ~25% going forward |
| Jayhawk pro forma annual revenue | ~US$76 million, consolidated 1 month and 2 days in Q4 FY26 |
| Bliss GVS Pharma capacity utilization | ~30%, with top line around ₹1,000 cr |
| Bliss GVS Pharma peak revenue potential from current gross block | ~₹3,000 cr (per management arithmetic) |